Manning Paul B

Manning Paul B is listed in filings as Director at Candel Therapeutics, Inc.. This profile follows SEC Form 4 activity through Apr 2, 2026, including purchase activity and sale activity. Recent filings connect the profile to Candel Therapeutics, Inc. (CADL), Liquidia Corporation (LQDA), Verrica Pharmaceuticals Inc. (VRCA), and Taysha Gene Therapies, Inc. (TSHA). The current snapshot covers public activity from Jun 27, 2024 to Apr 2, 2026. Reported amounts are shown as $22.6K to $2.3M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.